Marshall Wace, LLP Atea Pharmaceuticals, Inc. Transaction History

Marshall Wace, LLP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$3.31 - $4.04 $603,499 - $736,597	182,326 New	182,326 $603,000
Q2 2023 Aug 14, 2023	BUY	$3.21 - $5.06 $108,093 - $170,390	33,674 New	33,674 $125,000
Q1 2022 May 16, 2022	SELL	$5.5 - $9.19 $27,219 - $45,481	-4,949 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$7.67 - $44.59 $2.57 Million - $14.9 Million	-334,604 Reduced 98.54%	4,949 $44,000
Q3 2021 Nov 15, 2021	BUY	$21.33 - $35.06 $5.14 Million - $8.44 Million	240,847 Added 244.0%	339,553 $11.9 Million
Q2 2021 Aug 13, 2021	BUY	$19.22 - $59.08 $1.9 Million - $5.83 Million	98,706 New	98,706 $2.12 Million

112

52.4M

900

126K

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $270M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.